FLT3 and acute myeloid leukemia: Gilteritinib, a second-generation FLT3 inhibitor that is effective against both FLT3-ITD and FLT3-TKD [11, 12], has received global regulatory approval, including in Europe [13], the United States [14], Japan [15], and China [16], for the treatment of R/R FLT3mut+ AML.